Donor myoblast migration is a major limiting factor in the success of myoblast transfer therapy, a potential treatment for Duchenne muscular dystrophy. A possible strategy to promote the migration of donor myoblasts into host muscle is to enhance their proliferation and delay their fusion, two properties that are major characteristics of myoblasts in regenerating skeletal muscle in MyoD null (؊/؊) mice. Here we investigate whether the migration of MyoD (؊/؊) donor myoblasts into host muscle is enhanced in vivo. Sliced muscle grafts from male MyoD (؊/؊) or normal control (Balb/c) mice were transplanted into the muscles of female normal (Balb/c) host mice. Muscles were sampled at 1, 3, and 12 weeks after grafting, and the fate of male donor myoblasts within female host muscles determined by in situ hybridization with the mouse Ychromosome-specific Y-1 probe. MyoD (؊/؊) donor myoblasts migrated into host muscle continuously over 1, 3, and 12 weeks after grafting, in contrast with Balb/c donor myoblasts, whose overall numbers and migratory distances did not increase significantly after 1 week. These results strongly support a role for elevated donor myoblast proliferation and/or their delayed fusion in enhancing migration into host muscle in vivo, and endorse the use of either genetically engineered donor myoblasts, or the administration of exogenous myoblast mitogens to improve donor myoblast migration in myoblast transfer therapy.
INTRODUCTION
The transplantation of cultured muscle precursor cells (myoblasts) into host skeletal muscle is referred to as myoblast transfer therapy (MTT), and has potential for the treatment of skeletal myopathies [1] [2] [3] [4] [5] [6] . However, there are several major barriers to successful clinical MTT including the limited survival, migration, and fusion of injected cultured donor myoblasts within host muscle (reviewed in [2, 7, 8] ). The survival of injected donor myoblasts can be improved with host immunosuppression (reviewed in [7] ). We have recently demonstrated that certain immunosuppressants can also enhance the migration of donor myoblasts into host muscle [9] , and the distance moved is greater in dystrophic compared with nondystrophic control host muscles.
Several studies have investigated various methods of enhancing donor myoblast dispersal within host muscle after injection. Donor myoblast migration through the interstitial connective tissue can be facilitated by inducing the expression of enzymes that degrade the extracellular matrix [10 -13] , or host muscle regeneration [14] , and by altering the angle or method of injection [14, 15] . However, the damage caused to host muscle using the first two of these methods may limit their clinical significance. The administration of exogenous growth factors that enhance donor myoblast migration and/or proliferation may be an attractive and clinically viable alternative. This is supported by evidence that basic fibroblast growth factor (bFGF) increases the number of injected cultured donor myoblasts that survive in vivo [16, 17] , although whether bFGF acts as a survival, mitogenic, or chemotactic factor in this case is unclear. Several other growth factors that enhance myoblast chemotaxis and/or proliferation in vitro, including the insulin-like growth factors, platelet-derived growth factor, and leukemia inhibitory factor (reviewed in [18] ), are candidates for promoting the success of MTT. Alternatively, various factors can be administered by genetic modification of cultured donor myoblasts, since myoblasts are very easily and efficiently transformed in vitro to express new or altered genes that subsequently influence their behavior [19 -23] .
As a prelude to such potential genetic engineering of donor myoblasts, in the present study we investigate the hypothesis that enhanced myoblast proliferation and delayed fusion, posttransplantation will result in a larger number of donor myoblasts dispersing within host muscle tissue. It was recently demonstrated in vivo that myoblast proliferation is sustained and fusion delayed by 2-3 days during skeletal muscle regeneration in mice with a null (Ϫ/Ϫ) mutation in the myogenic regulatory gene MyoD [24] . This confirms in vitro studies with MyoD (Ϫ/Ϫ) myoblasts [25, 26] . To determine if elevated endogenous levels of myoblast proliferation and a delayed fusion phase promote donor myoblast migration in MTT, we examined the migration of MyoD (Ϫ/Ϫ) donor myoblasts within histocompatible normal (Balb/c) host muscle tissue. Since the majority of injected cultured donor myoblasts die within host muscle in the absence of host immunosuppression ( [27] ; reviewed in [7] ), whereas long-term donor myoblast survival is seen with whole and sliced muscle grafts [9, 28, 29] , we used the sliced muscle graft model of MTT to examine donor myoblast migration and fusion. Sliced muscle grafts from male MyoD (Ϫ/Ϫ) and normal control (Balb/c) donor mice were implanted in the tibialis anterior muscles of female normal (Balb/c) host mice. Grafted muscles were sampled at 1, 3, and 12 weeks after grafting and the number and location of male donor myoblasts within female host muscle sections analyzed by in situ hybridization with the Ychromosome (male)-specific Y-1 probe [9, 28 -30] . At 3 and 12 weeks after grafting there were significantly more male MyoD (Ϫ/Ϫ) than Balb/c donor myoblasts within female host muscle, and at 12 weeks MyoD (Ϫ/Ϫ) donor myoblasts were located much further from the graft compared to the Balb/c donors. These results demonstrate that MyoD (Ϫ/Ϫ) myoblasts have a greater propensity to migrate out from sliced muscle grafts in vivo, and strongly support the proposal that enhanced proliferation and/or delayed fusion of donor myoblasts can enhance MTT.
MATERIALS AND METHODS

Animals.
A total of 6 male MyoD null (Ϫ/Ϫ) (ages 6 -8 weeks) and 6 male Balb/c (ages 6 -8 weeks) donor mice and 12 female Balb/c (ages 6 -8 weeks) host mice were used. All animals were obtained from specific pathogen-free breeding stock at the Animal Resource Centre (Murdoch University, Western Australia) and were housed in the preclinical facility in the Department of Anatomy and Human Biology at The University of Western Australia. The MyoD (Ϫ/Ϫ) mice were originally a generous gift from Dr. Michael Rudnicki (McMaster University, Hamilton, Canada). Animals were housed in clean cages with food and water freely available. All animal procedures were carried out in accordance with the guidelines of the National Health and Medical Research Council of Australia, and with the prior approval of the Animal Ethics and Experimentation Committee at The University of Western Australia.
Sliced muscle grafting. Sliced muscle grafts were performed from male MyoD (Ϫ/Ϫ) and Balb/c donor mice into normal (Balb/c) female host mice. MyoD (Ϫ/Ϫ) and Balb/c mice are fully histocompatible. Male donor mice were sacrificed and both extensor digitorum longus (EDL) muscles removed. Donor EDL muscles were sliced longitudinally into three segments, and the midsegment was used for the graft to ensure that the connective tissue barrier on both sides of the graft had been removed. Female host mice were anesthetized (1.5% halothane delivered in oxygen) and a longitudinal incision in the skin was made from the knee to the ankle on the anterior surface of the hindlimb to expose the tibialis anterior (TA) muscle. A longitudinal incision was made in the TA muscle to a depth approximately midway through the muscle, and the donor EDL segment embedded within the host TA muscle. The incision was sutured closed with a single suture to keep the graft in place, and the skin was sutured closed. All female host mice received a male donor EDL sliced muscle graft to both TA muscles.
A total of 12 sliced muscle grafts were performed from male MyoD (Ϫ/Ϫ) mice into 6 female Balb/c mice, and 12 control male Balb/c grafts were performed into the remaining 6 female Balb/c mice. Two host mice from each group (i.e., 4 grafts) were sampled at 1, 3, and 12 weeks after grafting, and all grafted muscles were immerse-fixed in 3:1 methanol:acetic acid for 15 min, and then stored in 70% ethanol until processing through paraffin wax. Paraffin-embedded samples were cut, sections mounted on silanated slides, and the nuclei of male donor cells (originating in the grafts) determined by in situ hybridization with the digoxigenin (DIG)-labeled mouse Y-chromosome-specific Y-1 probe.
In situ hybridization. Tissue sections were dewaxed and rehydrated, fixed in fresh 4% paraformaldehyde, and then pretreated with Triton X-100 (Sigma; 0.5% in PBS), 0.2 N HCl, and proteinase K (Roche Biochemicals). Sections were postfixed in 4% paraformaldehyde and then prehybridized in hybridization solution (deionized formamide, 20X SSC, dextran sulfate) at 37°C. The DIG-labeled Y-1 probe was diluted in hybridization solution and applied to the tissue sections, and the sections were coverslipped and temporarily sealed with rubber cement. Sections were denatured on a hot plate at 100°C and then snap-cooled on ice before hybridizing overnight at 42°C. The following day the coverslips were removed, and the sections stringently washed in 2X, 1X, and 0.1X SSC. Detection of the DIGlabeled Y-1 probe hybridized to the Y-chromosome of male donor nuclei was carried out by antibody reaction (alkaline phosphataseconjugated anti-DIG, Roche Biochemicals) and color precipitation of alkaline phosphatase with nitroblue tetrazolium/5-bromo-4-chloro-3-inodyl-phosphate (NBT/BCIP, Roche Biochemicals).
Analysis. The location of Y-1-labeled male donor nuclei within female host muscle was determined on digitized images using MDPlot software (Microsoft). The total number and location (i.e., distance from the graft) of male donor myoblasts within female host muscle were compared for MyoD (Ϫ/Ϫ) and control Balb/c donors, to determine if the absence of MyoD affected the migration of donor myoblasts from sliced muscle grafts within normal host muscle. Distances were determined as the shortest straight-line distance that male donor nuclei were located from the nearest graft border. Two nonserial sections from each graft were analyzed using this method, and the data for all individual donor nuclei pooled for each group at each time point. Differences between the two treatment groups and between time points were tested for statistical significance using Kruskall-Wallis one-way analysis of variance, and were deemed significant at the 95% confidence level. Statistical analyses were conducted using Minitab 14.0 software (Microsoft).
RESULTS
Graft Morphology
In general, all sliced muscle grafts (from MyoD (Ϫ/Ϫ) and Balb/c donors) were almost fully regenerated by 1 week after grafting, with occasional inflammatory cells remaining within some grafts, interspersed among newly formed myotubes. Occasional myofibers sur-vived the grafting procedure (not shown), but the majority of donor myofibers underwent necrosis and regeneration. Since muscle graft regeneration in mice is usually complete by 1 week and this was the earliest time point examined in this study, myotubes had already been formed and there was no evidence of significant necrosis (or graft rejection) in any of the 24 grafts in the present study. At 3 weeks after grafting, no inflammatory cells remained and all grafts were composed of many densely packed, newly formed (centrally nucleated) myofibers, which contained predominantly male donor (i.e., Y-1-positive) nuclei (Figs. 1a  and 1b) . Graft morphology did not change significantly between 3 and 12 weeks after grafting. There were no obvious differences in the morphology of host muscles either between the groups or over time.
Numbers of MyoD (Ϫ/Ϫ) and Balb/c Donor Nuclei within Host Muscle
In situ hybridization with the Y-1 probe demonstrated male donor nuclei within female host muscle in all samples. At 1 and 3 weeks after grafting there were only occasional male donor nuclei located within the female host muscle and there were no obvious qualitative differences in the presence of male donor myoblasts within female host muscle between MyoD (Ϫ/Ϫ) (Fig. 1a) and Balb/c (Fig. 1b) donor sliced muscle grafts. This was confirmed by quantitative analysis, which showed that at 1 and 3 weeks after grafting there were no significant differences in the mean total number (i.e., fused and interstitial) of MyoD (Ϫ/Ϫ) and Balb/c male donor nuclei present within female host muscle ( Fig. 2) . At 12 weeks after grafting, the digitized images of the grafts obtained using the MDPlot program also demonstrated that more MyoD (Ϫ/Ϫ) (Fig. 3a) than Balb/c (Fig. 3b ) male donor nuclei were present within female host muscle, and more MyoD (Ϫ/Ϫ) (Fig.  1c) male donor nuclei were present within female host muscle tissue compared to the earlier time points (Fig.  1a) . This was in striking contrast to the sliced muscle grafts from male Balb/c donor mice at 12 weeks (Fig.  1d) , where the number of male donor nuclei within female host was similar to that at earlier times (Fig.  1b) . Quantitative analysis confirmed that at 12 weeks there were significantly more MyoD (Ϫ/Ϫ) donor nuclei within host muscle compared with Balb/c donor myoblasts (P ϭ 0.016; Fig. 2 ). There was a significant increase in the mean number of MyoD (Ϫ/Ϫ) donor nuclei within female host muscle between 3 and 12 weeks (P ϭ 0.034), indicating either that donor myoblast migration out from MyoD (Ϫ/Ϫ) sliced muscle grafts continued through these long-term time points or that donor myoblasts underwent proliferation within host muscle.
Distance of Migration of MyoD (Ϫ/Ϫ) and Balb/c Donor Myoblasts
The distance that MyoD (Ϫ/Ϫ) and Balb/c male donor nuclei were located from the nearest graft border was calculated from digitized images taken from tissue sections. At 1 week after grafting there was no significant difference between MyoD (Ϫ/Ϫ) and Balb/c donors in the mean distance that donor nuclei were located from the graft (Fig. 4) . There was also a similar pattern of distribution of MyoD (Ϫ/Ϫ) and Balb/c donor nuclei at this time, as shown by the data for the distance traveled by individual nuclei in Fig. 4 . In contrast, at both 3 and 12 weeks after grafting, MyoD (Ϫ/Ϫ) donor nuclei had migrated significantly further out from the graft and into host muscle compared with the Balb/c donors (Fig. 4) . The mean distance for MyoD (Ϫ/Ϫ) donor nuclei at 3 weeks was elevated by a single donor cell that was located approximately 2.7 mm from the graft (Fig. 4) , and at 12 weeks by at least eight donor nuclei that were located further than 2 mm away from the graft (Fig. 4) .
MyoD (Ϫ/Ϫ) donor nuclei continued to migrate through host muscle over time as indicated by significant increases in their mean distance from the graft between 1 and 3 weeks (P ϭ 0.025), and between 3 and 12 weeks (P ϭ 0.002), after grafting. Balb/c donor nuclei were located significantly closer to the graft at 3 weeks compared with the distance at 1 and 12 weeks (P Ͻ 0.005), although the mean distance was very similar at 1 and 12 weeks, suggesting that overall there was very little change in Balb/c donor myoblast migration over time.
DISCUSSION
In this study we have demonstrated unequivocally that the absence of the myogenic regulatory gene MyoD in donor myoblasts significantly enhances their migration into host muscle from sliced muscle grafts. The overall number of MyoD (Ϫ/Ϫ) donor nuclei within host muscle at each sampling time and their mean distance from the graft increased between 3 and 12 weeks. This indicates that MyoD (Ϫ/Ϫ) sliced muscle grafts provide a supply of donor myoblasts available to migrate into host muscle for a relatively long period of time (i.e., 12 weeks) or, alternatively, that once MyoD (Ϫ/Ϫ) donor myoblasts entered the host muscle they underwent extensive proliferation.
Although this study has clearly shown that myoblasts transplanted from MyoD (Ϫ/Ϫ) donor muscle have a greater capacity for dispersal within host muscle in vivo, the mechanisms by which this occurs are not clear. Skeletal muscle regeneration in MyoD (Ϫ/Ϫ) mice in vivo is transiently delayed, owing to a prolonged phase of myoblast proliferation and a delay in the onset of myoblast fusion [24] . Since the prolonged phase of MyoD (Ϫ/Ϫ) myoblast proliferation occurs during the regeneration phase within the first week after muscle grafting [24] , an early (i.e., 1 week) effect on myoblast migration was predicted. However, while male MyoD (Ϫ/Ϫ) donor myoblasts showed a greater propensity for migration into female host muscle compared to normal (Balb/c) donor myoblasts, this effect was seen only at 3 and 12 weeks after grafting. This suggests that the majority of both MyoD (Ϫ/Ϫ) and control Balb/c donor myoblast migration into host muscle occurred within the first week after grafting, and that the MyoD (Ϫ/Ϫ) donor myoblasts subsequently underwent further proliferation to result in larger numbers of donor myoblasts, and a greater mean migratory distance. While the sustained proliferation may simply reflect a disturbance of myoblast cell cycle regulation [24] , it has also been proposed that the MyoD (Ϫ/Ϫ) myoblasts may have similarities to stem cells [31, 32] , which are characterized by an extended capacity for proliferation. This issue remains to be resolved. The results for the Balb/c donor grafts are in accordance with our previous studies that showed no significant changes over time (up to 12 weeks) in the total number and the mean migratory distance of donor muscle nuclei out from normal sliced muscle grafts [9, 29] .
MyoD (Ϫ/Ϫ) donor myoblasts were located up to 3 mm from the graft, in contrast to the controls and our previous studies [33] , where normal donor myoblasts were observed no further than 2 mm from the graft. Therefore, we have demonstrated that MyoD (Ϫ/Ϫ) donor myoblasts have the potential to migrate up to 1 mm further into host muscle compared with normal control donor myoblasts (over 3 weeks). These distances, while highly significant in the mouse, are less striking in terms of the size of human muscles, and this emphasizes the importance of parallel studies in larger animal models. It is not clear whether the enhanced migration of MyoD (Ϫ/Ϫ) donor cells observed in the present study mainly reflects greater overall numbers of cells, or whether it truly reflects enhanced migration of individual myoblasts. It should be noted that although we have not specifically distinguished between myoblasts and other male donor cell types (e.g., fibroblasts), the specificity of the MyoD gene for myogenic cells indicates that the influence of the absence of this gene is reflected only in behavioral changes by myoblasts. It should be noted that the in situ hybridization technique with the Y-1 probe underestimates the total male donor nuclei present, as the probe binds to DNA in only a portion of the nucleus in the 5-m-thick section [34] . In this study we did not examine whether male donor cells migrated into other host muscles adjacent to the TA muscle. Such migration was not anticipated, since previous studies have demonstrated that donor myoblast migration between donor and host muscles is limited unless the donor and host muscle epimysia are disrupted [28, 35, 36] or host muscle regeneration is induced, which results in the release of myoblast chemoattractants [37] [38] [39] . However, several of these studies used immortalized C2C12 myoblasts rather than normal donor myoblasts in primary cultures [37, 38] , and the superior migration of C2C12 myoblasts was recently attributed to high levels of expression of matrix metalloproteinases compared with normal transplanted donor myoblasts [11] .
While we have not established exactly how the absence of MyoD promotes donor myoblast migration in vivo, the results of this study strongly support the proposal that enhancing donor myoblast proliferation increases myoblast dispersal throughout host muscle. This approach may be applied clinically, using the "ex vivo" approach, whereby cultured donor cells are genetically engineered to alter or induce the expression of certain genes prior to transplantation in vivo [19 -23] . Sastry and colleagues [19] demonstrated that transfection of cultured myoblasts with antisense vectors to integrin ␣6 resulted in enhanced myoblast proliferation and decreased differentiation. This ex vivo use of antisense therapy could similarly be applied to block other molecules whose absence has been shown to correlate with enhanced myoblast proliferation such as MyoD (as shown here), desmin [39b] , and transforming growth factor-␤ (TGF-␤) [40, 41] . A modification of this approach is to induce the overexpression of autocrine/ paracrine myoblast mitogens, such as hepatocyte growth factor [42, 43] , insulin-like growth factor-1 [21, 44 -46] , fibroblast growth factors [47, 48] , or leukemia inhibitory factor [49, 50] .
The most widely used technique to modify such gene expression in myoblasts is to apply viral vectors such as retroviruses [51, 52] and adenoviruses [23, [53] [54] [55] . Another way to deliver small peptide and nucleotide sequences into myoblasts is using "trojan" peptides such as penetratin and TAT, which can readily enter cells and transiently transfect target cells with "cargo" proteins (reviewed in [56] ).
An alternative approach is to administer exogenous growth factors that are known myoblast mitogens and/or chemoattractants. Culturing donor myoblasts in the presence of bFGF has been reported to increase myoblast dispersal in vivo; however, this may be a result of enhanced survival or proliferation [16, 17] . The enhanced myoblast proliferation resulting from neutralizing antibodies to TGF-␤ during skeletal muscle regeneration in vivo [40] suggests another method by which the growth factor environment in host muscle can be manipulated to promote the proliferation of injected cultured donor myoblasts in MTT.
In summary, this study has demonstrated that the absence of the myogenic regulatory factor MyoD in donor sliced muscle grafts results in enhanced migration of donor myoblasts into host muscle. This is most likely due to sustained endogenous proliferation of the transplanted donor myoblasts so that more donor myoblasts are available to emigrate into the host muscle prior to fusion. These results strongly support the notion that increased donor myoblast proliferation results in enhanced migration into host muscle, and endorses the use of techniques to improve donor myoblast proliferation in conventional MTT. 
